Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Plus R-CHOP in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma
NCT07649304Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoint: Ability to deliver at least 4 full cycles of Glofit-RCHOP. Planned start Jul 2027; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07649304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649304.